×
Palvella Therapeutics EBITDA 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Palvella Therapeutics ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Palvella Therapeutics EBITDA 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Palvella Therapeutics ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$151.4B
Bristol Myers Squibb (BMY)
$119.8B
Gilead Sciences (GILD)
$119.1B
Vertex Pharmaceuticals (VRTX)
$113.7B
CSL (CSLLY)
$83.5B
Regeneron Pharmaceuticals (REGN)
$75.5B
GSK (GSK)
$72.7B
Argenex SE (ARGX)
$39.5B
Alnylam Pharmaceuticals (ALNY)
$35.3B
BioNTech SE (BNTX)
$29B
BeiGene (ONC)
$22.2B
Biogen (BIIB)
$21B
Illumina (ILMN)
$20.9B
Moderna (MRNA)
$15.7B
Incyte (INCY)
$14.2B
Insmed (INSM)
$14B
Intra-Cellular Therapies (ITCI)
$13.5B
Genmab (GMAB)
$13.1B
Genmab (GNMSF)
$12.9B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.4B
Vaxcyte (PCVX)
$11.1B
Sarepta Therapeutics (SRPT)
$11B
Exact Sciences (EXAS)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Bio-Rad Laboratories (BIO.B)
$10B
QIAGEN (QGEN)
$9.7B
Repligen (RGEN)
$9.5B
Exelixis (EXEL)
$9.4B
Roivant Sciences (ROIV)
$8.1B